Lighthouse Investment Partners LLC Buys 7,348 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lighthouse Investment Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 141.6% in the 2nd quarter, Holdings Channel reports. The fund owned 12,536 shares of the biopharmaceutical company’s stock after acquiring an additional 7,348 shares during the quarter. Lighthouse Investment Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $13,176,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Mackenzie Financial Corp increased its position in shares of Regeneron Pharmaceuticals by 3.7% during the second quarter. Mackenzie Financial Corp now owns 57,964 shares of the biopharmaceutical company’s stock worth $60,922,000 after acquiring an additional 2,074 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock valued at $357,945,000 after purchasing an additional 2,270 shares in the last quarter. MBB Public Markets I LLC grew its position in Regeneron Pharmaceuticals by 2,095.9% in the second quarter. MBB Public Markets I LLC now owns 7,532 shares of the biopharmaceutical company’s stock valued at $7,916,000 after purchasing an additional 7,189 shares in the last quarter. DE Burlo Group Inc. grew its position in Regeneron Pharmaceuticals by 7.4% in the second quarter. DE Burlo Group Inc. now owns 8,690 shares of the biopharmaceutical company’s stock valued at $9,133,000 after purchasing an additional 600 shares in the last quarter. Finally, Decatur Capital Management Inc. grew its position in Regeneron Pharmaceuticals by 2.6% in the second quarter. Decatur Capital Management Inc. now owns 2,674 shares of the biopharmaceutical company’s stock valued at $2,810,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Piper Sandler increased their price target on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,039.96 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The firm has a market cap of $114.59 billion, a price-to-earnings ratio of 30.72, a P/E/G ratio of 3.72 and a beta of 0.12. The firm’s 50-day simple moving average is $1,129.87 and its 200 day simple moving average is $1,033.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the firm earned $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 9,270 shares of company stock valued at $10,695,833. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.